Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million

3 weeks ago 19

Jonathan Ponciano, The Motley Fool

Fri, February 27, 2026 astatine 10:18 AM CST 4 min read

On February 17, 2026, Casdin Capital disclosed a bargain of 1,662,193 shares of Relay Therapeutics (NASDAQ:RLAY), an estimated $11.86 cardinal commercialized based connected quarterly mean pricing, successful its Form 13F filing.

According to an SEC filing dated February 17, 2026, Casdin Capital accrued its holding successful Relay Therapeutics by 1,662,193 shares, bringing its full to 13,003,574 shares. The estimated transaction worth was $11.86 million, calculated utilizing the quarterly mean stock price. The quarter-end worth of the presumption accrued by $50.81 million, a fig that reflects some further purchases and banal terms movements during the period.

The bargain enactment brings Relay Therapeutics to 6.83% of Casdin Capital’s 13F reportable AUM aft the quarter.
Top holdings aft the filing:
- NASDAQ: WGS: $391.11 cardinal (24.3% of AUM)
- NASDAQ: RVMD: $205.28 cardinal (12.8% of AUM)
- NASDAQ: BLFS: $144.04 cardinal (8.9% of AUM)
- NASDAQ: LAB: $113.64 cardinal (7.1% of AUM)
- NASDAQ:RLAY: $110.01 cardinal (6.8% of AUM)
As of Friday, RLAY shares were priced astatine $10.95, up 235% implicit the past twelvemonth and vastly outperforming the S&P 500’s astir 15% summation successful the aforesaid period.

Metric

Value

Price (as of Friday)	$10.95
Market Capitalization	$1.9 billion
Revenue (TTM)	$8.36 million
Net Income (TTM)	($297.59 million)

Relay develops precision medicines with a absorption connected tiny molecule therapeutics for targeted oncology and familial diseases, including pb candidates RLY-4008, RLY-2608, and RLY-1971.
The steadfast operates a clinical-stage biotechnology model, generating gross chiefly done collaboration and licence agreements with partners specified arsenic D. E. Shaw Research and Genentech.
It serves pharmaceutical companies and healthcare providers focused connected precocious coagulated tumor treatments and familial illness therapies.

Relay Therapeutics is simply a clinical-stage biotechnology institution specializing successful the find and improvement of precision medicines for oncology and familial diseases. The company's strategy leverages precocious computational modeling and partnerships to accelerate the improvement of small-molecule therapies targeting cardinal illness pathways. Relay's attack includes proprietary macromolecule question investigation and a pipeline of caller cause candidates.

Momentum successful biotech tin beryllium fleeting, but adding to a presumption amid a stunning banal tally suggests condemnation that upcoming objective catalysts inactive are not afloat reflected successful the price.

Relay enters 2026 with respective plaything factors. Management expects aggregate information disclosures this year, including Phase 1 information successful PIK3CA driven vascular anomalies and updates connected bosom crab triplet strategies tied to its pb asset, zovegalisib. The cause is already successful a Phase 3 proceedings for HR positive, HER2 antagonistic metastatic bosom cancer.

Financially, Relay finished 2025 with astir $555 cardinal successful cash, currency equivalents and investments and expects that superior to money operations into 2029. Meanwhile, the full-year nett nonaccomplishment totaled $276.5 cardinal arsenic probe spending remained elevated.

Within a portfolio concentrated successful innovative biotech names, the presumption ranks among the larger holdings. And for semipermanent investors, the thesis hinges little connected past year’s banal illustration and much connected execution. If 2026 milestones validate the Phase 3 strategy and grow into familial disease, today’s adhd could look similar disciplined sizing up of imaginable worth inflection.

Read Entire Article